Biohaven .(US:BHVN) Globenewswire·2025-09-09 23:21Core Viewpoint - Rosen Law Firm is reminding investors who purchased Biohaven Ltd. securities between March 24, 2023, and May 14, 2025, of the September 12, 2025, deadline to serve as lead plaintiff in a class action lawsuit [1] Group 1: Class Action Details - A class action lawsuit has been filed against Biohaven Ltd. for allegedly making false and misleading statements regarding its drug candidates, which may have negatively impacted investors [4] - Investors who wish to join the class action can do so without any out-of-pocket fees through a contingency fee arrangement [1][2] - The lawsuit claims that the defendants overstated the regulatory prospects of the drug troriluzole for treating spinocerebellar ataxia and the efficacy of BHV-7000 for bipolar disorder, leading to significant damages for investors when the truth was revealed [4] Group 2: Legal Representation - Investors are encouraged to select qualified legal counsel with a proven track record in securities class actions, as many firms may not have the necessary experience or resources [3] - Rosen Law Firm has a history of successful settlements, including the largest securities class action settlement against a Chinese company at the time, and has recovered hundreds of millions of dollars for investors [3]